- PROFESSOR Medicine, Liver Diseases
BS, The College of Holy Cross
MD, Tufts University School of Medicine
Mount Sinai Medical Center
Mount Sinai Medical Center
Rhode Island Hospital & Brown University
- Dr. Henry C. Bodenheimer, Jr. is an international authority on acute and chronic inflammatory liver disease, specializing in viral hepatitis and primary biliary cirrhosis. Dr. Bodenheimer has extensive experience in all forms of therapy for liver disease including liver transplantation. A widely respected clinician, teacher, and lecturer. Dr. Bodenheimer was a key participant in the initial trials establishing a role for recombinant alpha interferon in the treatment of both hepatitis C and B. In addition to a busy consultation office practice, Dr. Bodenheimer is the Clinical Director of Liver Diseases and Medical Director of the Recanati Miller Transplantation Institute. Dr. Bodenheimer is Professor of Medicine at Mount Sinai School of Medicine and is the Program Director of the Liver Diseases Fellowship Program at Mount Sinai. Dr. Bodenheimer serves on several nationally prominent panels, establishing standards of clinical care for patients with liver diseases. He currently is the Chairman of the Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Dr. Bodenheimer is currently conducting clinical research trials to advance the treatment of patients with viral hepatitis C and B. He has authored more than seventy scientific articles and has lectured on liver disease throughout the world.
Mount Sinai School of Medicine
Master of Arts ad eundem
1980 - 1981
Haffenreffer Fellow in Medicine
Rhode Island Hospital
Member, A.O.A-Medical Honor Society
Tufts University School of Medicine
Member, A.E.D - Premedical Honor Society
The College of the Holy Cross
1967 - 1971
The College of the Holy Cross
Hepatitis C Hepatitis B transplantation Primary biliary Cirrhosis Antivirals
Projects currently open for patient enrollments:\r\n
\r\n1.\tA randomized, double-blind comparison of three doses of Entecavir vs. Lamivudine in immunocompetent subjects with chronic hepatitis b infection with viremia on Lamivudine therapy. (GC0-00-0192)\r\n
\r\nThis study will evaluate the safety and effectiveness of different doses of a new hepatitis B after the virus has developed resistance to Lamivudine.\r\n
\r\n2.\tA randomized multi-center trial to evaluate pegylated interferon plus Ribavirin at two different doses for patients with chronic hepatitis C and relaspse after combination therapy or non-response after monotherapy or combination therapy. (GC0-00-0048)\r\n
\r\nThis study will assess the effectiveness of two different dosages of long acting (pegylated) interferon given with a second anti-viral (ribavirin) to patients whose hepatitis C infections remain after prior attempts at treatment. Pegylated interferon is a new chemical formulation of recombinant alpha interferon given once per week by injection.\r\n
\r\n3.\tMulti-center, randomized, open-label study of the safety and efficacy of interferon alfa-2b plus ribavirin for the treatment of HCV infection in HIV-infected persons: Daily versus tiw inteferon dosing. (GC0-99-1114)\r\n
\r\nThis study will assess the effectiveness and tolerance of interferon plus ribavirin in patients co-infected with hepatitis C and HIV.\r\n
\r\n Projects currently ongoing but closed to new patient enrollment:\r\n
\r\n1.\tA Phase III, randomied, multi-center, efficacy and safety study examining the effects of the duration of treatment and the daily dose of ribavirin in patients with chronic hepatitis C virus infection treated with the combination of peg interferon alfa-2a and ribavirin. (GC0-98-1088)\r\n
\r\n2.\tIntron A and ribavirin for the treatment of patients with chronic hepatitis C, normal ALT and not previously treated with interferon. (GC0-99-665).\r\n
\r\n3.\tA study of extended Lamivudine treatment for hepatitis B patients previously enrolled in phase II or phase III Lamivudine trials. (GC0-96-649).\r\n
\r\n4.\tA long-term epidemiologic study of patients who have evidence of possible durable response to Lamivudine in phase II or phase III trials of Lamivudine.\r\n (GC0-97-071).\r\n
\r\nProjects to be begun in the near future:\r\n
\r\n1.\tA randomized study to compare the effectiveness and tolerability of pegylated interferon alfa-2a alone vs. pegylated interferon alfa-2a plus ribavirin for the treatment of patients with hepatitis C. \r\n
\r\n2.\tA randomized study of the pharmokinetics, efficacy and safety of Adefovir for treatment of patients with hepatitis B previously untreated with a nucleoside analog. \r\n
\r\n3.\tA study of the effect of ethnicity on the activity of Adefovir for treatment of patients with hepatitis B previously untreated with a nucleoside analog. \r\n
Kim-Schluger HL, Bodenheimer HC. Liver Transplantation. In: Hurst JW, editor. Medicine for the Practicing Physician. Appleton and Lange; 1996.
Lindsay KL, David GL, Schiff ER, Bodenheimer H, Balart LA, Dienstag JL. Response to Higher Doses of Interferon Alfa-2b in Patients With Hepatitis C: a Randomized Multicenter trial. Hepatology 1996; 24: 1034-1040.
Bodenheimer H, Lindsay KL, Davis GL, Lewis JH, Thung` S, Seeff LB. Tolerance and Eficiacy of Oral Ribavirin Treatment of Chronic Hepatitis C: a Multicenter Trial. Hepatology 1997; 26: 473-477.
Fiel MI, Schiano T , Bodenheimer HC, Thung SN, King TW, Varma C, Miller CM, Brunt EM, Starnes S, Prass CY. Hereditary Hemochromatosis in Liver Transplantation. Liver Transpl Surg 1999; 5: 50-56.
Fiel MI, Schiano T, Guido M, Thung S, Lindsay KL, Davis GL, Lewis JH, Seeff LB, Bodenheimer HC. Increased Hepatic Iron Deposition Resulting From Treatment of Chronic Hepatitis C With Ribavirin. Am J Gastroenterology 2000; 113: 35-39.
Brodsky N, Jaffe DL, Kim-Schluger L, Bodenheimer HC, Bach N. Decompensated Liver Disease associated with Hereditary Hemorrhagic Telangiectasia.;.
Abrams J, Bodenheimer H, Thung S, Miller C, Jaffe DL. Significant Recurrence of Primary Sclerosing Cholangitis following Liver Transplantation.;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Bodenheimer is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.